Whitehawk expands ADC pipeline with option for five new programs using CPT113 linker-payload

Whitehawk Therapeutics announced an option agreement with Hangzhou DAC Biotechnology that grants access to the linker-payload CPT113 for use in up to five additional antibody drug conjugate programs. This represents a meaningful expansion of the company's ADC pipeline in oncology, potentially diversifying its therapeutic development portfolio beyond existing programs. The timing coincides with Hangzhou DAC's presentation of clinical data at the ASCO Annual Meeting for DXC006, which uses the same CPT113 technology, offering early validation of the platform.

For retail investors, this deal signals Whitehawk's strategy to broaden its pipeline without developing linker-payload technology in-house, which could accelerate timelines and reduce development risk. However, the option structure means the company has not yet committed to all five programs. Watch for follow-on disclosures about which specific targets Whitehawk selects for development and any financial terms of exercising the options, as these will determine the actual impact on the company's clinical roadmap and cash runway.